Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19235902 | VASCULAR EMBOLIC SYSTEM | June 2025 | February 2026 | Allow | 8 | 1 | 0 | No | No |
| 19082426 | SENESCENCE INHIBITOR | March 2025 | January 2026 | Allow | 10 | 2 | 0 | No | No |
| 18955985 | HANGTAIMYCIN DERIVATIVES AND THEIR PREPARATION METHODS AND APPLICATION | November 2024 | September 2025 | Allow | 10 | 2 | 1 | Yes | No |
| 18954145 | ACTRII PROTEINS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) | November 2024 | December 2025 | Allow | 12 | 2 | 1 | Yes | No |
| 18917707 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | October 2024 | February 2025 | Allow | 4 | 1 | 0 | No | No |
| 18883592 | Long-Acting GLP-1 Compound | September 2024 | October 2025 | Abandon | 13 | 1 | 1 | No | No |
| 18834736 | USE OF COLLAGEN HYDROLYSATE IN PREVENTION AND/OR TREATMENT OF FOOD CRAVING | July 2024 | December 2025 | Allow | 17 | 2 | 0 | Yes | No |
| 18774846 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND LIVER DISORDERS | July 2024 | January 2025 | Allow | 7 | 1 | 1 | No | No |
| 17855222 | ANTIBACTERIAL PRODUCTS | June 2024 | March 2026 | Abandon | 44 | 2 | 1 | Yes | No |
| 18722415 | ISOCYCLOSPORIN A FOR TOPICAL TREATMENT OF OCULAR DISEASES | June 2024 | October 2025 | Allow | 16 | 2 | 0 | Yes | No |
| 18742845 | MATRIX METALLOPROTEASE-CLEAVABLE AND SERINE OR CYSTEINE PROTEASE-CLEAVABLE SUBSTRATES AND METHODS OF USE THEREOF | June 2024 | October 2025 | Allow | 16 | 1 | 0 | No | No |
| 18719490 | DUAL TARGETING FOR CELL-SPECIFIC DELIVERY TO THE CENTRAL NERVOUS SYSTEM | June 2024 | August 2025 | Allow | 15 | 2 | 0 | No | No |
| 18637124 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | April 2024 | March 2025 | Allow | 11 | 1 | 0 | No | No |
| 18626600 | SYSTEMS AND METHODS FOR TREATMENT OF HEARING USING DIHEXA | April 2024 | March 2025 | Allow | 11 | 1 | 0 | No | No |
| 18582180 | HETERODIMERIC FC CYTOKINES AND USES THEREOF | February 2024 | August 2024 | Allow | 6 | 1 | 1 | No | No |
| 18436212 | TREATMENT OF AGE-RELATED MACULAR DEGENERATION | February 2024 | September 2025 | Abandon | 19 | 1 | 0 | No | No |
| 18415415 | MATRIX METALLOPROTEASE-CLEAVABLE AND SERINE OR CYSTEINE PROTEASE-CLEAVABLE SUBSTRATES AND METHODS OF USE THEREOF | January 2024 | January 2026 | Allow | 24 | 1 | 1 | No | No |
| 18414112 | MODIFIED ANTI-INFLAMMATORY PROTEINS AND METHOD OF USE | January 2024 | June 2025 | Allow | 17 | 1 | 0 | Yes | No |
| 18541682 | NOVEL INSULIN ANALOGUES AND USES THEREOF | December 2023 | August 2024 | Allow | 8 | 2 | 0 | No | No |
| 18527402 | CYCLOTHEONELLAZOLEA, AND SYNTHETIC METHOD THEREFOR, AND APPLICATION METHOD THEREOF | December 2023 | January 2026 | Abandon | 26 | 1 | 0 | No | No |
| 18518000 | METHODS AND COMPOSITIONS FOR DELIVERY OF VIRAL VECTORS ACROSS THE BLOOD-BRAIN BARRIER | November 2023 | December 2024 | Allow | 13 | 0 | 0 | No | No |
| 18518227 | PREPARATION METHOD AND APPLICATION OF HIGH-PURITY PLANT-DERIVED RECOMBINANT HUMAN SERUM ALBUMIN | November 2023 | September 2024 | Allow | 10 | 2 | 1 | No | No |
| 18516047 | HETERODIMERIC FC CYTOKINES AND USES THEREOF | November 2023 | August 2025 | Allow | 21 | 2 | 0 | Yes | No |
| 18511430 | SITE-SPECIFIC BIO-CONJUGATION METHODS AND COMPOSITIONS USEFUL FOR NANOPORE SYSTEMS | November 2023 | July 2025 | Allow | 20 | 1 | 0 | Yes | No |
| 18504561 | LIQUID FORMULATIONS COMPRISING MUTANT FGF-21 PEPTIDE PEGYLATED CONJUGATES | November 2023 | March 2025 | Allow | 16 | 1 | 0 | Yes | No |
| 18486310 | ULTRA-LONG ACTING INSULIN-FC FUSION PROTEIN AND METHODS OF USE | October 2023 | October 2024 | Allow | 12 | 0 | 0 | Yes | No |
| 18240295 | PEPTIDE COMPOUNDS AND PEPTIDE CONJUGATES FOR THE TREATMENT OF CANCER THROUGH RECEPTOR-MEDIATED CHEMOTHERAPY | August 2023 | November 2024 | Allow | 15 | 1 | 0 | No | No |
| 18447990 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND LIVER DISORDERS | August 2023 | October 2025 | Allow | 26 | 2 | 0 | Yes | No |
| 18355539 | CTLA-4 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF | July 2023 | March 2025 | Allow | 20 | 0 | 1 | Yes | No |
| 18350543 | IL-7R-ALPHA-GAMMA BINDING COMPOUNDS | July 2023 | February 2024 | Allow | 7 | 1 | 1 | No | No |
| 18219159 | HIGHLY POTENT ISVD COMPOUNDS CAPABLE OF SUBSTITUTING FOR FVIII(A) | July 2023 | February 2024 | Allow | 8 | 0 | 1 | Yes | No |
| 18213779 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | June 2023 | December 2023 | Allow | 5 | 1 | 0 | No | No |
| 18339152 | SYSTEMS AND METHODS FOR TREATMENT OF HEARING USING DIHEXA | June 2023 | January 2024 | Allow | 7 | 0 | 1 | No | No |
| 18331667 | BIOACTIVE PEPTIDES HAVING DETRIMENTAL EFFECTS ON PEST SLUGS | June 2023 | November 2025 | Allow | 29 | 2 | 1 | No | No |
| 18327916 | COMPOSITIONS AND METHODS INVOLVING PROBIOTIC MOLECULES | June 2023 | April 2025 | Abandon | 22 | 1 | 1 | No | No |
| 18320697 | GENERAL AMYLOID INTERACTION MOTIF (GAIM) | May 2023 | November 2024 | Allow | 18 | 1 | 0 | Yes | No |
| 18306965 | Silk-Hyaluronic Acid Based Tissue Fillers and Methods of Using the Same | April 2023 | December 2025 | Allow | 32 | 1 | 1 | Yes | No |
| 18303642 | Compositions and Methods for Diagnosis and Treatment of Cancer | April 2023 | September 2025 | Allow | 29 | 2 | 0 | No | No |
| 18133767 | Fluorocarbon-Linked Peptide Formulation | April 2023 | December 2024 | Abandon | 20 | 0 | 1 | No | No |
| 18298056 | PHARMACEUTICAL COMBINATION THERAPY AND PREVENTION WITH APROTININ + NIRMATRELVIR OF SARS-CoV-2 AND/OR DISEASE ASSOCIATED WITH THIS INFECTION, INCLUDING COVID-19 | April 2023 | December 2025 | Abandon | 32 | 2 | 1 | Yes | No |
| 18181942 | Activatable Therapeutic Peptides and Uses Thereof | March 2023 | June 2025 | Allow | 28 | 1 | 1 | No | No |
| 18116166 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | March 2023 | August 2023 | Allow | 6 | 1 | 0 | Yes | No |
| 18021645 | PEPTIDE-BASED DOPA CONTAINING ADHESIVE GELS | February 2023 | July 2024 | Allow | 17 | 1 | 1 | No | No |
| 18165081 | LIQUID FORMULATIONS COMPRISING MUTANT FGF-21 PEPTIDE PEGYLATED CONJUGATES | February 2023 | August 2023 | Allow | 6 | 0 | 0 | Yes | No |
| 18164802 | GLP-1 AND GLUCAGON DUAL AGONIST PEPTIDES WITH IMPROVED BIOLOGICAL STABILITY | February 2023 | January 2026 | Allow | 36 | 3 | 0 | Yes | No |
| 18162833 | PEPTIDES HAVING SPECIFICITY FOR THE LUNGS | February 2023 | January 2025 | Abandon | 23 | 1 | 0 | No | No |
| 18161799 | CTLA-4 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF | January 2023 | December 2025 | Allow | 35 | 2 | 1 | No | No |
| 18158746 | BONE-PROMOTING THERMORESPONSIVE MACROMOLECULES | January 2023 | March 2025 | Abandon | 25 | 1 | 1 | No | No |
| 18157081 | ACE INHIBITORY PEPTIDE COMPOSITION DERIVED FROM GINKGO PROTEIN AND PREPARATION METHOD AND APPLICATION THEREOF | January 2023 | June 2024 | Allow | 16 | 1 | 0 | No | No |
| 18156633 | PHARMACEUTICAL PREPARATION FOR IMPROVING ABSORPTION AND POSTPRANDIAL HYPOGLYCEMIC ACTION OF INSULIN | January 2023 | November 2024 | Allow | 22 | 1 | 1 | No | No |
| 18147796 | THERMALLY STABLE FGF7 POLYPEPTIDE AND USE OF THE SAME | December 2022 | August 2025 | Allow | 32 | 2 | 0 | No | No |
| 18090259 | PHOSPHATIDYLSERINE-BINDING CONJUGATES | December 2022 | December 2024 | Allow | 24 | 1 | 1 | No | No |
| 18064719 | STAPLED PEPTIDE AND USE THEREOF IN PREPARATION OF DRUG FOR TREATING PANCREATIC CANCER | December 2022 | September 2024 | Allow | 21 | 0 | 1 | No | No |
| 18058131 | MEANS AND METHODS FOR TREATING AND DIAGNOSING FIBROSIS OR FIBROSIS-ASSOCIATED DISEASES | November 2022 | November 2025 | Allow | 36 | 2 | 1 | Yes | No |
| 17990629 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND LIVER DISORDERS | November 2022 | July 2023 | Allow | 18 | 1 | 1 | No | No |
| 18054596 | RELAXIN-2 FUSION PROTEIN ANALOGS AND METHODS OF USING SAME | November 2022 | October 2025 | Allow | 35 | 1 | 1 | Yes | No |
| 17982883 | UBIQUITIN HIGH AFFINITY CYCLIC PEPTIDES AND METHODS OF USE THEREOF | November 2022 | May 2024 | Allow | 18 | 1 | 0 | No | No |
| 18052529 | COMPLEXATION OF NUCLEIC ACIDS WITH DISULFIDE-CROSSLINKED CATIONIC COMPONENTS FOR TRANSFECTION AND IMMUNOSTIMULATION | November 2022 | August 2024 | Abandon | 22 | 0 | 1 | No | No |
| 17997801 | REGENTIDE-041 AND COMPOSITION COMPRISING REGENTIDE-041 FOR IMPROVING SKIN CONDITION | November 2022 | February 2026 | Allow | 40 | 1 | 1 | Yes | No |
| 17997808 | COMPOSITION COMPRISING REGENTIDE-012 OR REGENTIDE-013 FOR IMPROVING SKIN CONDITION | November 2022 | November 2025 | Allow | 36 | 1 | 0 | No | No |
| 17977247 | FIBRONECTIN TYPE III DOMAIN-BASED PROTEIN AND APPLICATION THEREOF | October 2022 | March 2025 | Allow | 28 | 1 | 1 | Yes | No |
| 17996460 | COMPOSITIONS COMPRISING CYS-PEPTIDES | October 2022 | February 2026 | Abandon | 40 | 6 | 1 | No | No |
| 17961438 | NOVEL INSULIN ANALOGUES AND USES THEREOF | October 2022 | December 2023 | Allow | 14 | 0 | 0 | Yes | No |
| 17936424 | High-activity memory-improving derivative peptide and use thereof | September 2022 | August 2023 | Allow | 11 | 1 | 0 | Yes | No |
| 17956031 | PEPTIDES AND OTHER AGENTS FOR TREATING PAIN AND INCREASING PAIN SENSITIVITY | September 2022 | April 2024 | Allow | 19 | 1 | 0 | Yes | No |
| 17914277 | COMPOSITIONS AND METHODS FOR MODULATING MYOSIN SUBFRAGMENT-2 COILED COIL STABILITY AND METHODS FOR USING THEM | September 2022 | January 2026 | Allow | 40 | 0 | 1 | Yes | No |
| 17932302 | Methods of Preventing or Treating Diseases, Conditions, or Disorders Associated With Chemotherapy | September 2022 | November 2024 | Allow | 26 | 1 | 1 | No | No |
| 17940460 | MIR-145 MICELLES FOR MITIGATING ATHEROSCLEROSIS | September 2022 | August 2025 | Allow | 36 | 2 | 1 | No | No |
| 17802388 | CHEMICALLY-STABILIZED ALLOSTERIC MODULATORS OF LEUCINE-RICH REPEAT KINASE 2 (LRRK2) | August 2022 | October 2025 | Allow | 38 | 0 | 1 | Yes | No |
| 17818583 | CHIMERIC INHIBITOR MOLECULES OF COMPLEMENT ACTIVATION | August 2022 | November 2023 | Allow | 15 | 0 | 0 | Yes | No |
| 17818318 | ARC-BASED CAPSIDS AND USES THEREOF | August 2022 | May 2024 | Abandon | 22 | 1 | 0 | No | No |
| 17862617 | DRUG COMPOSITION, METHOD FOR TREATING INFECTION, DISINFECTING COMPOSITION, AND DRUG ADJUVANT | July 2022 | October 2024 | Allow | 27 | 2 | 1 | No | No |
| 17858724 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | July 2022 | March 2023 | Allow | 8 | 1 | 0 | Yes | No |
| 17854986 | COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND DEVICES AND METHODS OF PRODUCTION AND USE THEREOF | June 2022 | May 2025 | Allow | 35 | 3 | 1 | Yes | No |
| 17758113 | Long-Acting GLP-1 Compound | June 2022 | March 2026 | Allow | 45 | 2 | 1 | No | No |
| 17846686 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DISEASE | June 2022 | February 2025 | Allow | 32 | 2 | 0 | No | No |
| 17842286 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | June 2022 | October 2022 | Allow | 4 | 0 | 0 | Yes | No |
| 17839026 | NOVEL COMPOUNDS AND THERAPEUTICS USES THEREOF | June 2022 | June 2024 | Allow | 25 | 1 | 1 | Yes | No |
| 17837082 | AMINO ACID-SPECIFIC BINDER AND SELECTIVELY IDENTIFYING AN AMINO ACID | June 2022 | January 2025 | Allow | 31 | 2 | 1 | Yes | No |
| 17835689 | COLLAGEN DAILY WITH ENZYME INHIBITORS FOR ANTI-AGING | June 2022 | September 2023 | Allow | 15 | 2 | 1 | Yes | No |
| 17782573 | PEPTIDE CONJUGATES AND METHODS OF USE | June 2022 | November 2025 | Allow | 41 | 0 | 1 | Yes | No |
| 17782603 | PEPTIDE-BASED SYNTHETIC CHLORIDE ION TRANSPORTERS | June 2022 | November 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17829180 | PROHEMOSTATIC PROTEINS FOR THE TREATMENT OF BLEEDING | May 2022 | May 2024 | Allow | 23 | 1 | 0 | Yes | No |
| 17825243 | COMPOSITIONS AND METHODS OF CLOSTRIDIODIDES DIFFICILE TREATMENT, DECOLONIZATION, AND PREVENTION | May 2022 | June 2024 | Allow | 25 | 2 | 1 | Yes | No |
| 17750530 | EFFICIENT DELIVERY OF THERAPEUTIC MOLECULES TO CELLS OF THE INNER EAR | May 2022 | March 2024 | Allow | 22 | 0 | 1 | Yes | No |
| 17778624 | METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF TYPE 1 DIABETES | May 2022 | December 2025 | Allow | 43 | 2 | 1 | No | No |
| 17744540 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | May 2022 | April 2024 | Allow | 23 | 0 | 1 | Yes | No |
| 17776217 | LIPID NANO DRUG DELIVERY SYSTEM TARGETING BRAIN LESION AND PREPARATION METHOD AND APPLICATION THEREOF | May 2022 | January 2026 | Allow | 44 | 1 | 1 | No | No |
| 17775871 | CXCR4 ANTAGONIST PEPTIDES | May 2022 | September 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17775034 | SOLID COMPOSITIONS COMPRISING A GLP-1 AGONIST, AN SGLT2 INHIBITOR AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID | May 2022 | September 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17761255 | ANTI-TUMOR PEPTIDE AND USE THEREOF | May 2022 | September 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17768636 | USE OF ESCULENTIN AND ITS DERIVATIVES FOR USE IN THE TREATMENT OF CYSTIC FIBROSIS | April 2022 | November 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17718758 | PEPTIDE FOR TREATING INFLAMMATION AND WOUNDS | April 2022 | October 2025 | Allow | 42 | 1 | 1 | No | No |
| 17768142 | ANALGESIC AND ANESTHETIC PEPTIDES AND OTHER AGENTS | April 2022 | January 2026 | Abandon | 45 | 1 | 1 | No | No |
| 17709608 | PHARMACEUTICAL COMBINATION THERAPY AND PREVENTION WITH APROTININ + MOLNUPIRAVIR OF SARS-CoV-2 AND/OR DISEASE ASSOCIATED WITH THIS INFECTION, INCLUDI COVID-19 | March 2022 | October 2023 | Abandon | 19 | 3 | 0 | Yes | No |
| 17704522 | ANTI-ANGIOGENIC TREATMENT USING VLO4 WITH A BLOCKING PEPTIDE | March 2022 | March 2024 | Allow | 24 | 2 | 0 | No | No |
| 17692024 | LIQUID FORMULATIONS COMPRISING MUTANT FGF-21 PEPTIDE PEGYLATED CONJUGATES | March 2022 | January 2023 | Allow | 10 | 2 | 0 | No | No |
| 17688588 | PURIFICATION OF FACTOR VIII SUBSPECIES | March 2022 | April 2024 | Allow | 25 | 0 | 1 | Yes | No |
| 17753420 | POLYPEPTIDE MONOLAYER WITH HIGH POTENTIAL AND HYDROPHOBICITY, AND PREPARATION METHOD AND APPLICATION THEREOF | March 2022 | February 2026 | Abandon | 48 | 2 | 1 | No | No |
| 17682782 | ASPARTIC PROTEASE-TRIGGERED ANTIFUNGAL HYDROGELS | February 2022 | December 2025 | Abandon | 45 | 3 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MIKNIS, ZACHARY J.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 6.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner MIKNIS, ZACHARY J works in Art Unit 1658 and has examined 247 patent applications in our dataset. With an allowance rate of 78.5%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 31 months.
Examiner MIKNIS, ZACHARY J's allowance rate of 78.5% places them in the 47% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by MIKNIS, ZACHARY J receive 1.96 office actions before reaching final disposition. This places the examiner in the 49% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by MIKNIS, ZACHARY J is 31 months. This places the examiner in the 54% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +24.9% benefit to allowance rate for applications examined by MIKNIS, ZACHARY J. This interview benefit is in the 71% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 28.3% of applications are subsequently allowed. This success rate is in the 51% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 53.6% of cases where such amendments are filed. This entry rate is in the 80% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 87% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 64.8% are granted (fully or in part). This grant rate is in the 70% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.